26 August 2016 - Women with uterine fibroids stand to gain routine access to a non-surgical treatment on the NHS for the first time, after NICE endorsed Gedeon Richter's Esmya (ulipristal acetate) as an treatment option.

NICE has published updated guidelines that support the use of Esmya, a selective progesterone receptor modulator which acts by blocking receptors of the hormone progesterone, after clinical trials showed that it provides rapid control of bleeding, reduces anaemia and shrinks the size of fibroids.

Doctors can now prescribe up to four courses of the drug as a first-line treatment for patients presenting with heavy menstrual bleeding and uterine fibroids 3cm or more in diameter.

Last month, the PBAC rejected a submission for Esyma for use as intermittent treatment.

Read Pharma Times article